服用抗血栓药物对脑叶出血患者预后的影响

目的 探讨口服抗血栓药物对脑叶出血患者预后的影响.方法 回顾性分析我院神经抢救中心2002年1月至2012年12月收治的145例脑叶出血患者的临床资料.将使用口服用抗血栓药物患者与未用药组患者的预后和临床资料进行对比分析.并对死亡患者的相关因素进行统计分析.结果 服用抗血栓药物组患者的平均年龄为(77±12)岁,未服用抗血栓药物组(67±13)岁(P＜0.05).在用药组患者中,合并冠心病者比例显著高于未用药组.用药组患者的平均出血量为(47 ±29) ml,未用药组的(28±19) ml(P＜0.05).脑叶出血患者的病死率与患者的年龄及出血量存在正相关性.结论 服用抗血栓药物可加重脑叶出血患者的出血量,增加脑叶出血患者不良预后的风险.

Characteristics of oral anfithrombotic drugs concurrent with lobar hemorrhage

Objective To investigate the characteristics of oral antithrombotic drugs concurrent with lobar hemorrhage and the related factors of the prognosis of patients with lobar hemorrhage.Methods The clinical data of 145 lobar hemorrhage patients treated in the neural rescue center in our hospital from January 2002 to December 2012 was analyzed.We conducted a comparative analysis between the patients receiving oral antithrombotic agents and untreated group.The related factors of death of the patients were analyzed.Results The mean age of treated group patients was 77 ± 12 years,which was significantly higher than that of the untreated group.The proportion of patients with coronary heart disease in treatment group was significantly higher than that in the untreated group.The average amount of bleeding in treatment group patients was （47 ± 29）ml,significantly more than the untreated group of （28 ± 19）ml.Mortality in patients with lobar hemorrhage was positive correlated with the patient＇s age and the amount of bleeding.Conclusion Oral antithrombotic drugs increase the amount of bleeding in patients with lobar hemorrhage,which may increase the risk of a poor prognosis of patients with lobar hemorrhage.